Department of Psychiatry and Behavioral Medicine, Carilion Clinic-Virginia Tech Carilion School of Medicine, Roanoke, VA, USA.
Psychiatr Q. 2012 Sep;83(3):371-83. doi: 10.1007/s11126-012-9208-4.
To review the available data behind the use of lamotrigine in unipolar depression and common comorbid conditions. A PubMed based literature review was conducted using keywords related to lamotrigine, depression, anxiety, post traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), and personality disorders. A large number of trials using lamotrigine for unipolar depression and various comorbid conditions were reviewed. A major limitation behind the majority of studies was a limited course of the treatment phase. The most robust data was found among studies that followed patients for over 8 weeks, and used higher dosages. Patients with comorbid anxiety states appeared to benefit. Patients with borderline personality disorder also appeared to benefit. The benefits of lamotrigine in unipolar depression have been inconsistently noted in a number of studies. This is due in part to short treatment phases, atypical domains of benefit and different patient populations across studies. Patients with more treatment-resistance, comorbid anxiety and borderline personality disorder may be more able to benefit from lamotrigine.
回顾拉莫三嗪在单相抑郁和常见共病情况下应用的现有数据。使用与拉莫三嗪、抑郁、焦虑、创伤后应激障碍（PTSD）、强迫症（OCD）和人格障碍相关的关键词，在 PubMed 上进行了文献回顾。对大量使用拉莫三嗪治疗单相抑郁和各种共病情况的试验进行了综述。大多数研究的一个主要局限性是治疗阶段的时间有限。在随访患者超过 8 周并使用较高剂量的研究中，发现了最有力的数据。有共病焦虑状态的患者似乎受益。边缘型人格障碍患者似乎也受益。拉莫三嗪在单相抑郁中的疗效在多项研究中不一致。这部分是由于治疗阶段较短，受益的非典型领域以及不同研究中的患者人群不同。更多治疗抵抗、共病焦虑和边缘型人格障碍的患者可能会从拉莫三嗪中获益更多。
